CCDC3 and Insulin resistance: CCDC3, as a novel TAp63 target, acts as an endocrine molecule that may target hepatocytes and alleviates the pathological changes that are associated with HFD-induced steatosis, and attenuates the progression or deterioration of diseases associated with insulin resistance via an anti-lipogenesis effect in liver (Fig. 7k).